Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Meixner, Eva [VerfasserIn]   i
 Wermes, Laura [VerfasserIn]   i
 Hoeltgen, Line [VerfasserIn]   i
 Dinges, Lisa A. [VerfasserIn]   i
 Sandrini, Elisabetta [VerfasserIn]   i
 Harrabi, Semi B. [VerfasserIn]   i
 Seidensaal, Katharina [VerfasserIn]   i
 Hoegen-Saßmannshausen, Philipp [VerfasserIn]   i
 Vinsensia, Maria [VerfasserIn]   i
 König, Laila [VerfasserIn]   i
 Arians, Nathalie [VerfasserIn]   i
 Debus, Jürgen [VerfasserIn]   i
 Hörner-Rieber, Juliane [VerfasserIn]   i
Titel:Hematologic toxicity profiles and the impact of hemoglobin nadir and transfusion on oncologic outcome in definitive radiochemotherapy for cervical cancer
Verf.angabe:Eva Meixner, Laura Wermes, Line Hoeltgen, Lisa Antonia von Diest, Elisabetta Sandrini, Semi Harrabi, Katharina Seidensaal, Philipp Hoegen-Saßmannshausen, Maria Vinsensia, Laila König, Nathalie Arians, Jürgen Debus and Juliane Hörner-Rieber
E-Jahr:2024
Jahr:27 November 2024
Umfang:12 S.
Illustrationen:Illustrationen
Fussnoten:Gesehen am 01.05.2025
Titel Quelle:Enthalten in: Cancers
Ort Quelle:Basel : MDPI, 2009
Jahr Quelle:2024
Band/Heft Quelle:16(2024), 23, Artikel-ID 3986, Seite 1-12
ISSN Quelle:2072-6694
Abstract:Background/Objectives: Definitive radiochemotherapy with concomitant cisplatin 40 mg/m2 weekly represents the standard of care for locally advanced cervical cancer. Current studies (KEYNOTE-A18 and INTERLACE) are intensifying this regimen at the cost of increased hematologic toxicity. We aimed to evaluate influencing factors on hematotoxicity to ensure the safe application of radiochemotherapy. Methods: We retrospectively analyzed 147 patients, who received definitive radiochemotherapy between 2000 and 2019 and evaluated laboratory parameters before, after, and at each chemotherapy cycle to evaluate the occurrence, course, and profile of hematotoxicity. Further, we assessed the impact of hemoglobin levels and transfusion on oncological outcomes. Results: In a high-risk cervical cancer population with 82.3% of women with FIGO ≥ III stage, the 1-, 2-, and 5-year rates of overall survival (OS) were 89.1%, 74.7%, and 63.3%, and local control (LC) rates were 90.1%, 86.1%, and 75.0%, respectively. Grade 3 leukopenia was present in 2.1% and grade 3 anemia in 4.3%. No higher grade ≥ 4 hematotoxicity was observed. Absolute hemoglobin levels significantly reduced after the fourth cycle, with a median time from the start of therapy to hemoglobin nadir of 36 days. A lower hemoglobin nadir (<9 g/dL) was significantly associated with inferior LC. Red blood cell transfusion was applied in 44.9% of the women; the necessity of transfusion was significantly correlated to inferior OS, LC, and distant control. Conclusions: Our results suggest the need for special consideration of increased hematotoxicity and consistent implementation of anemia therapy, particularly from the fourth RT week onwards, to enable full-course definitive radiochemotherapy for locally advanced cervical cancer patients.
DOI:doi:10.3390/cancers16233986
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

kostenfrei: Volltext: https://doi.org/10.3390/cancers16233986
 kostenfrei: Volltext: https://www.mdpi.com/2072-6694/16/23/3986
 DOI: https://doi.org/10.3390/cancers16233986
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:anemia
 chemoradiation
 cisplatin
 hematotoxicity
 lymph node dissection
K10plus-PPN:1924110911
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69340852   QR-Code
zum Seitenanfang